Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan 11;14(1):e21101.
doi: 10.7759/cureus.21101. eCollection 2022 Jan.

Hypertrophic Cardiomyopathy and Atrial Fibrillation: A Review

Vishnu Palyam  1 , Ahmad T Azam  2 , Oladipo Odeyinka  3 , Rasha Alhashimi  4 , Sankeerth Thoota  5 , Tejaswini Ashok  6 , Ibrahim Sange  7
Affiliations
Review

Hypertrophic Cardiomyopathy and Atrial Fibrillation: A Review

Vishnu Palyam et al. Cureus. .

Abstract

Hypertrophic cardiomyopathy (HCM) is an inherited cardiological condition that exhibits various clinical symptoms. The leading cause of atrial fibrillation (AF) in patients with HCM is advanced diastolic dysfunction and left atrial dilatation and remodeling. In addition to the gradual symptomatic and functional decline caused by AF, there is an increased risk of thromboembolic disease and mortality, especially if there is a rapid ventricular rate or obstruction of the left ventricular outflow tract. The mainstay of management of AF in HCM is a combination of non-pharmacological lifestyle and risk factor modification, long-term anticoagulation, and rhythm control with anti-arrhythmic medications, septal ablation, and radiofrequency catheter ablation. This article has examined the development of AF in HCM, its clinical symptomatology, and its impact, highlighting its management and the mortality associated with AF in HCM.

Keywords: atrial fibrillation; atrial fibrillation management; hypertrophic cardiomyopathy; left atrial ablation; obstructive cardiomyopathy.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Pathogenesis of atrial fibrillation in hypertrophic cardiomyopathy
Figure 2
Figure 2. Mitral regurgitation with an increase of thickening of the left ventricular wall
LA, left atrium; MR, mitral regurgitation; Ao, aorta; MV, mitral valve; LV, left ventricle
See this image and copyright information in PMC

References

    1. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Marian AJ, Braunwald E. Circ Res. 2017;121:749–770. - PMC - PubMed
    1. Contribution à l’étude des rétrécissements de l’orifice ventriculo-aortique. Vulpian A. Arch Physiol. 1868;3:220–222.
    1. Prevalence of clinically apparent hypertrophic cardiomyopathy in Germany-an analysis of over 5 million patients. Husser D, Ueberham L, Jacob J, et al. PLoS One. 2018;13:0. - PMC - PubMed
    1. Association of race with disease expression and clinical outcomes among patients with hypertrophic cardiomyopathy. Eberly LA, Day SM, Ashley EA, et al. JAMA Cardiol. 2020;5:83–91. - PMC - PubMed
    1. [Sudden cardiac death in familial hypertrophic cardiomyopathy. Identification of high-risk patients] Pellnitz C, Geier C, Perrot A, Dietz R, Osterziel KJ, Haverkamp W. Dtsch Med Wochenschr. 2005;130:1150–1154. - PubMed

LinkOut - more resources